Rentschler Biopharma has expanded its CDM service offerings at its UK site with a new lentiviral vector (LVV) manufacturing toolbox.
The Stevenage facility, which specialises in the development and production of advanced therapies, will now have LVV manufacturing services on top of the existing adeno-associated viral (AAV) vector services the company already offered.
According to Rentschler, LVVs are becoming more prominent in the advanced therapy space, as they have great potential in treating a number of genetic diseases.
This includes rare conditions like beta-thalassemia and various forms of cancer.
Rentschler's advanced therapies facility offers client-specific solutions suitable for clients looking to accelerate their viral vector programmes at every stage, with the AAV and LVV toolboxes being license-free.
Customers will also benefit from the company's proprietary cell line, which can be use for research and development purposes in advanced therapy projects.
According to Rentschler, it has contributed to nearly 25% of the FDA-approved biopharmaceuticals in 2023, and the company wants to continue on this track record.
Christiane Bardroff, COO at Rentschler Biopharma, commented: “We made a strategic investment in the cell and gene therapy sector, starting with adeno-associated viral vector services, so we could offer our development and manufacturing expertise and sector experience to support innovators in this fast-developing space. We are now pleased to build on our success and augment this offering with lentiviral vectors. ”
Robert Panting, General Manager, ATMP, added: “By integrating lentiviral vector process development and manufacturing to our services, we are better serving the market by meeting the growing needs of the evolving and vibrant global advanced therapies sector.”